Case Form
Find Out if You Potentially Qualify for a Financial Reward by filling out the form.
Repare Therapeutics issued a press release, on February 12, 2024, “announc[ing] . . . that it will regain global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), following termination of its collaboration agreement with Roche.” The press release stated that “Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche’s pipeline and evolving external factors.”
Following this news, on February 13, 2024, Repare’s stock price fell over 15%.